Harrow Inc
HROW38.790USD
+0.220+0.57%
收盤 08/27, 16:00（美東）報價延遲15分鐘
1.42B總市值
虧損本益比TTM
關於 Harrow Inc 公司
Harrow, Inc. 是一家眼科藥品公司。該公司致力於爲美國市場發現、開發和銷售眼科藥品。它提供全面的處方藥和非處方藥產品組合。它擁有北美品牌眼科藥品組合的商業權利，所有這些產品均以 Harrow 的名義銷售。它擁有並經營 ImprimisRx，這是一家專注於眼科的藥物配製企業。它擁有各種產品的美國商業權利：IHEEZO、VEVYE、TRIESENCE、VIGAMOX、ILEVRO、FLAREX、NATACYN、ZERVIATE 等。VIGAMOX（鹽酸莫西沙星滴眼液）0.5%，是一種氟喹諾酮類抗生素滴眼液，用於治療由敏感菌株引起的細菌性結膜炎。 IHEEZO（鹽酸氯普魯卡因眼用凝膠）3%是一種用於眼表麻醉的低粘度凝膠。
公司簡介
公司代碼HROW
公司名稱Harrow Inc
上市日期Feb 08, 2013
CEOMr. John P. Saharek
員工數量382
證券類型Ordinary Share
年結日Feb 08
公司地址1A Burton Hills Blvd
城市NASHVILLE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編37215
電話16157334731
網址https://www.harrow.com/
公司代碼HROW
上市日期Feb 08, 2013
CEOMr. John P. Saharek
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.89M
+11.03%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
收入明細
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
其他
65.27%
持股股東
持股股東
佔比
Opaleye Management Inc.
10.55%
Baum (Mark L)
7.80%
BlackRock Institutional Trust Company, N.A.
6.09%
Private Capital Management
5.26%
The Vanguard Group, Inc.
5.03%
其他
65.27%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
18.79%
Investment Advisor
18.12%
Hedge Fund
17.30%
Individual Investor
15.72%
Research Firm
2.46%
Bank and Trust
0.35%
Pension Fund
0.29%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
其他
26.87%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
345
26.63M
72.57%
-2.99M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
2023Q1
246
23.86M
79.81%
+1.57M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Opaleye Management Inc.
3.94M
10.72%
-4.80K
-0.12%
Jun 04, 2025
Baum (Mark L)
2.60M
7.08%
+461.94K
+21.61%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.27M
6.2%
-1.07K
-0.05%
Mar 31, 2025
Private Capital Management
1.89M
5.15%
+195.64K
+11.54%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
5.07%
-6.65K
-0.36%
Mar 31, 2025
Kaufman (Daniel)
1.68M
4.59%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
956.84K
2.61%
+49.80K
+5.49%
Mar 31, 2025
Geode Capital Management, L.L.C.
774.08K
2.11%
+52.97K
+7.35%
Mar 31, 2025
Boll (Andrew R)
777.84K
2.12%
+209.75K
+36.92%
Apr 21, 2025
State Street Global Advisors (US)
786.48K
2.14%
-41.22K
-4.98%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月6日 週三
更新時間: 8月6日 週三
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.81%
Invesco Dorsey Wright Healthcare Momentum ETF
1.59%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.12%
iShares U.S. Pharmaceuticals ETF
0.49%
First Trust Small Cap Growth AlphaDEX Fund
0.37%
Invesco Dorsey Wright SmallCap Momentum ETF
0.36%
iShares Micro-Cap ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.11%
Fidelity Small-Mid Multifactor ETF
0.1%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.81%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.59%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.12%
iShares U.S. Pharmaceuticals ETF
佔比0.49%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.37%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.36%
iShares Micro-Cap ETF
佔比0.22%
ProShares Ultra Nasdaq Biotechnology
佔比0.12%
Invesco Nasdaq Biotechnology ETF
佔比0.11%
Fidelity Small-Mid Multifactor ETF
佔比0.1%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
